At UBC, we house one of the largest longitudinal population-based MS databases in the world. The database currently holds over 7500 patients followed for over 25 years. There is a huge scope for research projects. We welcome collaborations; please contact Dr Helen Tremlett for further details (firstname.lastname@example.org).
My group is often looking for talented masters, PhD students or post-docs; all are welcome to apply!
15. Tremlett H, Paty D, Devonshire V The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65:1919-1923.
16. Tremlett H, Paty D, Devonshire V. Disability progression in MS is slower than previously reported. Neurology. 2006;66:172-177.
17. Tremlett H, Devonshire V. Does the season or month of birth influence disease progression in multiple sclerosis? Neuroepidemiology 2006;26:195-198
18. Tremlett H, Devonshire V. Is late onset multiple sclerosis associated with a worse outcome? Neurology 2006;67:954-959
19. Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger J. Petkau J. Liver test abnormalities in multiple sclerosis: findings from placebo treated patients. Neurology 2006;67:1291-1293
20. Sayao AL, Devonshire V, Tremlett H. Longitudinal Follow-up of Benign MS at 20 years. Neurology. 2007 Feb 13;68(7):496-500.
21. Tremlett H, Oger J Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Multiple Sclerosis 2008; 14:94-105
22. Tremlett H, Zhao Y, Devonshire V. The natural history of secondary-progressive multiple sclerosis Multiple Sclerosis 2008. 14: 314–324
23. Forwell S, Brunham S, Tremlett H, Morrison W, Tentzerakis S, Bogle N, Oger J. Primary and non-primary fatigue in multiple sclerosis. International Journal of MS Care. 2008; 10:14-20
24. Koch M, De Keyser J, Tremlett H Timing of birth and disease progression in multiple sclerosis. Multiple Sclerosis 2008; 14:793-798.
25. Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety 2008 17(6):565-76.
26. Tremlett H, Zhao Y, Joseph J, Devonshire V and the UBC MS Clinic Neurologists. Relapses in multiple sclerosis are age and time-dependent. J Neurol Neurosurg Psychiatry 2008;79;1368-1374
27. Tremlett H, van der Mei I, Pittas F, Blizzard L, Paley G, Mesaros G, Woodbaker R, Nunez M, Dwyer T, Taylor B, Ponsonby AL. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008; 31: 271-279
28. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology. 2009 Mar;256(3):374-81
29. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y and the UBC Neurologists. The impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73 1616-1623
Medical research expertise
– pharmacoepidemiology, epidemiology, multiple sclerosis
– side-effects of the immunomodulatory drugs for multiple sclerosis
– natural history of multiple sclerosis: disease progression and relapses
– prognosis and predictors of disease progression in multiple sclerosis